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Abstract
Background: Assessing the long-term cost of colorectal cancer (CRC) increases our understanding of the disease
burden. The aim of this paper is to estimate the long-term costs of CRC care by stage at diagnosis and phase of
care in the Spanish National Health Service.
Methods: Retrospective study on resource use and direct medical cost of a cohort of 699 patients diagnosed and
treated for CRC in 2000–2006, with follow-up until 30 June 2011, at Hospital del Mar (Barcelona). The Kaplan-Meier
sample average estimator was used to calculate observed 11-year costs, which were then extrapolated to 16 years.
Bootstrap percentile confidence intervals were calculated for the mean long-term cost per patient by stage.
Phase-specific, long-term costs for the entire CRC cohort were also estimated.
Results: With regard to stage at diagnosis, the mean long-term cost per patient ranged from €20,708 (in situ) to
€47,681 (stage III). The estimated costs increased at more advanced stages up to stage III and then substantially
decreased in stage IV. In terms of treatment phase, the mean cost of the initial period represented 24.8 % of the
total mean long-term cost, whereas the cost of continuing and advanced care phases represented 16.9 and 58.3 %,
respectively.
Conclusions: This study is the first to provide long-term cost estimates for CRC treatment, by stage at diagnosis
and phase of care, based on data from clinical practice in Spain, and it will contribute useful information for future
studies on cost-effectiveness and budget impact of different therapeutic innovations in Spain.
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Background
In Europe, colorectal cancer (CRC) represents the sec-
ond most common type of cancer (13.0 % in the total
number of incident cancers) [1]; in Spain, it ranks first
in incidence (15.0 %) and second in both male and fe-
male mortality, after lung and breast cancer, respectively.
In recent years, new drugs such as bevacizumab,
cetuximab and panitumumab have been developed for
treatment of advanced CRC, promising potential im-
provements in patient outcomes [2, 3]. The introduction
of these new drugs has increased the economic burden
of CRC care, raising questions about the viability of its
coverage in the public system [4, 5]. Thus, there is in-
creasing interest in quantifying and evaluating the long-
term costs by stage at diagnosis and phase of care. The
assessment of long-term cost of CRC allows a better un-
derstanding of the disease burden and provides a useful
source of information for cost-effectiveness studies on
different preventive or alternative treatment initiatives.
Most studies that provide estimates of the long-term
cost of CRC were conducted in the United States [6–9],
but to our knowledge, there are no such studies in
Spain. Because of differential organisation of health sys-
tems and different practice patterns and settings, the
transferability of country specific results is not always
possible, so further studies specific to Spain are needed.
Because recently introduced drugs have significantly in-
creased the cost of the treatment, some studies in Spain
have focused on chemotherapy treatments or on a par-
ticular phase of the disease [10, 11]. Cots et al. [12]
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examined the costs of CRC treatment by stage at diag-
nosis and phase of care but did not take into account pa-
tient loss during the follow-up period, nor did they have
complete survival information for the cases included in
the analysis. Despite this limitation, their analysis pro-
vides a basis for long-term cost estimation. The aim of
this paper is to estimate the long-term costs of CRC care
by stage at diagnosis and phase of care in the Spanish
National Health Service context.
Methods
Study design
Retrospective cohort study of 699 patients diagnosed
and treated for CRC from 2000–2006 at Hospital del
Mar (Barcelona), with follow-up until 30 June 2011. A
prospective analysis of survival and long-term costs was
also performed. The Hospital del Mar belongs to the
Public Use Hospital Network of Catalonia.
Data sources
A database was built linking different data sources re-
lated to CRC care: the Hospital Cancer Registry, the
clinical-administrative information system and the cost
accounting system. The Hospital Cancer Registry identi-
fied the CRC cases, their TNM stage at the time of diag-
nosis (TNM classification of the American Joint
Committee on Cancer) [13] as well as the date and
cause of death. The TNM system is based on the size
and/or extent of the primary tumour (T), the amount of
spread to nearby lymph nodes (N), and the presence of
metastasis (M). In turn, information on the date and
cause of death is obtained annually through a record
linkage procedure between the Hospital Cancer Registry
and the Catalonian Mortality Registry. The clinical-
administrative information system provided information
on health care episodes (inpatient discharges, surgeries,
outpatient visits, chemotherapy and radiotherapy ses-
sions) and health care services related to them (length
of stay in conventional inpatient care units, length of
stay in intensive care unit, operating room, doses of
chemotherapy drugs, antiemetic and other related
drugs, outpatient dispensing drugs, number and com-
plexity of radiotherapy sessions, laboratory and radi-
ology tests). Unit costs were obtained from the cost
accounting system, which is an Activity Based Costing
analytical accounting system implemented over 20 years
ago.
This study was performed in accordance with the eth-
ical standards of the Declaration of Helsinki and com-
plied with the legal regulations on data confidentiality
(Ley Orgánica 15/1999, de 13 de diciembre, de Protección
de Datos de Carácter Personal). It was also approved by
the Ethics Committee of Hospital del Mar.
Attributable cancer-related cost
It is difficult to discern from administrative data-
bases which episodes of care (inpatient admission,
outpatient or emergency visit) are clearly related to
cancer care.
All episodes of care from the Medical Oncology,
Radiotherapy, Gastroenterology, General and Digestive
Surgery or Palliative Care Units were considered to be
related to CRC treatment (and including comorbidities).
All episodes of care related to the Internal Medicine
Unit were included if this unit had diagnosed the
disease.
Cost histories assessment
To assess the cost of the episodes of care in the period
considered, unit costs from 2005 were obtained from the
cost accounting system. Cost values in this year were
considered to be representative of the study period.
Assigning the same year-specific cost unit to each
healthcare service, any differences in cost over time
would reflect changes in resource utilisation and not in
price deviations arising from pharmaceutical companies’
policies or different production structures over the study
period.
Taking into account the date of each care episode and
service, monthly costs were assessed (cost histories). The
year of diagnosis was considered the baseline year (Year 0)
with costs from later calendar years being discounted
at 3 % [14].
Phase-specific costs
The time between diagnosis and death was divided into
three phases: the initial care phase covered the time of
diagnosis and the first course of therapy (surgery and/
or adjuvant treatments). Its completion marked the
transition from the initial care phase to the continuing
care phase, which included the time of monitoring care
following initial treatment. Finally, the advanced care
phase began when local recurrence or metastasis ap-
peared or when palliative treatments were adminis-
tered. The transition to the advanced phase was
determined by the confirmation of metastasis or recur-
rence by a hospital discharge report, the administration
of advanced disease, palliative chemotherapy, radiother-
apy treatment or admission into the Palliative Care
Unit. An algorithm was developed in order to deter-
mine the duration of the phases and specific phase of
care costs for each patient.
Estimation of long-term costs
Long-term or lifetime costs are defined as the cumula-
tive cost from the date of diagnosis to the date of death,
but in long-term cost estimations, some patients are not
actually followed until their death [15, 16], so these cost
Corral et al. BMC Health Services Research  (2016) 16:56 Page 2 of 8
histories are censored. However, this introduces a prob-
lem: total cost is underestimated when based on the full
sample of censored and non-censored cases, since pa-
tients who withdraw from the study, or who remain alive
at the end of the follow-up period, will continue to incur
costs after the study is over. On the other hand, if long-
term cost is only estimated for patients with uncensored
costs, the estimator is biased towards patients with
shorter survival times because longer survival times are
more likely to be censored. Therefore, censored data can
lead to biased estimates if the appropriate analysis tech-
niques are not used.
To account for censored data, some researchers have
applied the standard survival analyses techniques [17].
The Kaplan-Meier method applied to cost-to-event ana-
lysis (where costs are treated as potentially right-
censored survival times) leads to bias because the re-
quirement of independent censoring times and death
times may not be fulfilled [18, 19]. For this reason, a
number of alternative techniques have been proposed in
the literature for estimating mean total costs in the pres-
ence of censoring [16, 18, 20, 21].
In this analysis, patient records were collected from
the period 2000–2006 and were followed up through
2011, for a maximum of 11 years of evaluation, a time
horizon unlikely to be adequate for evaluating long-term
costs among patients diagnosed with non-advanced can-
cer. Thus, modeling techniques for the analysis of cen-
sored cost data were used to estimate long-term health
care costs attributable to CRC [20, 22]. This estimation
was carried out in two steps. First, long-term costs of
CRC care were estimated for the 2000–2011 study
period directly from observable data. We then extrapo-
lated the estimated costs, adding 5 years from observed
cost data (i.e. years 11 to 16), taking into account the
care phases.
Costs for years 1 to 11 were estimated using the
nonparametric Kaplan-Meier Sample Average (KMSA)
estimator, which takes into account the censorship of
survival and cost data. This method assumes that de-
tailed patient cost histories are available and makes
use of this information when estimating the mean
total cost. The KMSA estimator computes costs by
adding up expected costs incurred during each time
interval, calculated as the product of the probability
of surviving to that time interval (Kaplan-Meier esti-
mates of survival), and the average sample cost
among patients who survive to the beginning of the
interval.
Let C be the average total cost for treating patients
with CRC over the study period. We divide the entire
time period into K survival times [tj, tj + 1) of one-month
duration each. Since the cost histories are recorded, C
can be decomposed as C1…CK.
The Kaplan-Meier estimator of the probability of sur-
viving to time (month) j is given by
S
⌢
j ¼
Y
j:tj≤t
nj−dj
nj
Where n is the number of subjects, with survival time
at tj, with dj being the number of deaths at tj, and nj being
the number of subjects at risk at tj.
The estimate of the average total cost is given by
C
⌢
1 ¼
X
j
CjSj
Where Cj is the observed mean cost in month j among
survivors to month j and Sj is the disease-specific sur-
vival probability at month j. This estimator takes into ac-
count the information of each patient at every observed
month.
Costs for years 11 through 16 were extrapolated, based
on the assumption that cohort-specific, average annual
costs were constant for years beyond the available data
until the year before the final year of life (continuing
costs). These continuing phase costs were estimated as
the average annual continuing phase cost from the sub-
set of patients in each stage who were not considered as
outliers (lying beyond the two standard deviations of the
geometric mean). In addition, we assumed that medical
care costs in the advanced care phase were the same for
patients who lived beyond the 11-year study period, re-
gardless of time from diagnosis; advanced care or ter-
minal costs were thus estimated as the annualised
average advanced-care phase cost among patients in the
relevant stage who died of CRC.
We estimated the extrapolated average total cost given
by
C
⌢
2 ¼
X16
y¼11
dyCdy þ 1−dy
 
Csy
 
Sy
Where dy is the hazard of dying at year y, Cdy is the es-
timation of the annual terminal cost in year y, Csy is the
estimation of the annual cost in the continuing phase in
year y, and Sy is the disease-specific survival probability
at year y. The annual hazard of dying and the survival
probability in years 11 to 16 were estimated from Weibull
models of survival. Finally, long-term cost estimates were
obtained by adding C
⌢
1 and C
⌢
2.
Long-term costs were reported by TNM stage at the
time of diagnosis. Bootstrap percentile confidence in-
tervals were calculated for the mean long-term cost per
patient by stage at diagnosis from re-sampling the data
10,000 times. All analyses were done through R 3.1.0
software.
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Phase-specific cost estimates for the entire CRC cohort
Long-term cost estimation required calculating continuing
care and advanced phase costs for CRC patients who sur-
vived at least 11 years. For completeness, phase-specific
long-term costs for the entire CRC cohort were also esti-
mated. For patients living fewer than 11 years from diag-
nosis, specific phase of care costs were estimated by
means of the clinical algorithm developed in order to de-
termine the duration of the phases for each patient.
Results
Patient characteristics and survival
A total of 699 cases of CRC were analysed, of which 512
(73.2 %) were diagnosed with colon cancer and 187 (26.8
%) were diagnosed with rectal cancer. Table 1 presents
age, gender, staging distribution of patients at diagnosis,
and treatments received. Table 2 shows the distribution
of deaths, mean survival time and mean follow-up time
by TNM stage at diagnosis. The mean survival time de-
creased from in situ cases to stage IV diagnoses, ranging
from 137.5 to 21.2 months.
Long-term costs estimates
Table 3 shows the observed mean cost, KMSA estima-
tion, cost extrapolation and mean long-term cost by
TNM stage at diagnosis. Observed mean cost per patient
ranged from €9634 among in situ patients to €41,550 in
stage III. The KMSA estimator showed an estimated
total cost that ranged from €17,692 among in situ cases
to €44,934 among patients diagnosed at stage III. Taking
into account the extrapolation up to five years beyond
the observed costs, the estimated mean long-term costs
ranged from €20,708 among in situ cases to €47,681 for
stage III. In all cases, the estimated costs increased in
more advanced stages up to stage III and then decreased
substantially in stage IV. Figure 1 shows the observed
mean costs over the first 11 years and the total long-
Table 1 Patient characteristics
Colon Rectum Total
N 512 187 699
Age (years)
Mean 70.4 70.5 70.5
Median 73.0 72.0 73.0
Sex (%)
Male 53.9 59.4 55.4
Female 46.1 40.6 44.6
Year of diagnosis (%)
2000 13.3 12.3 13.0
2001 14.3 15.5 14.6
2002 15.0 14.4 14.9
2003 17.0 13.4 16.0
2004 17.0 13.9 16.2
2005 11.5 12.8 11.9
2006 11.9 17.6 13.4
TNM Stage (%)
In situ 6.6 3.2 5.7
I 11.7 14.4 12.5
II 25.8 25.1 25.6
III 23.2 29.4 24.9
IV 21.3 18.7 20.6
Unknown 11.3 9.1 10.7
Surgery (%)
Patients 68.9 75.4 70.7
Surgical procedure
Right hemicolectomy 27.7 1.1 18.6
Left hemicolectomy 5.5 0.7 3.8
Sigmoidectomy 18.9 1.1 12.8
Other colon resections 9.2 2.2 6.8
Anterior resection of rectum 3.9 27.7 12.1
Abdominoperineal resection 0.0 14.2 4.9
Other rectal resections 0.8 10.9 4.2
Liver metastases resection 3.5 3.4 3.5
Other metastases resection 1.8 2.2 1.9
Other procedures 28.8 36.3 31.4
Chemotherapy (%)
Patients 30.1 47.1 34.6
Intention
Neoadjuvant 1.4 27.7 11.0
Adjuvant 29.0 26.2 28.0
Advanced disease - Palliative 63.7 44.1 56.6
Unknown 5.9 2.0 4.5
Table 1 Patient characteristics (Continued)
Treatment scheme
Fluorouracil +/− Levamisole 20.0 43.9 28.5
Capecitabine +/− Irinotecan/Oxaliplatin 23.8 16.6 21.3
Irinotecan - Fluorouracil +/− Leucovorin 14.7 17.1 15.6
Oxaliplatin - Fluorouracil +/− Leucovorin 12.1 7.5 10.4
Cetuximab - Irinotecan 10.3 3.2 7.8
Others 19.1 11.8 16.5
Radiotherapy (%)
Patients 7.2 48.7 18.3
Intention
Radical 39.5 74.5 64.4
Palliative 60.5 25.5 35.6
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term costs until year 16 after diagnosis by stage. The differ-
ence between the observed costs and estimated long-term
costs decreased in cases diagnosed at advanced stages.
Table 4 shows the long-term costs of CRC treatment
by TNM stage at diagnosis and phase of care. The mean
cost of the initial care phase represented 24.8 % of the
total mean long-term cost, whereas the cost of continu-
ing and advanced phases represented 16.9 and 58.3 %,
respectively. Higher costs were found during the initial
care and advanced care phase in all stages, with the ex-
ception of cases diagnosed in situ and at stage I, where
the mean cost of the continuing care phase represented
56.0 and 50.5 % of the total mean long-term cost,
respectively.
The initial and continuing care phase costs decreased
in relative weight as disease stage progressed. The initial
phase costs ranged from 35.0 % of the total at stage I to
5.1 % at stage IV, and the continuing care phase from
50.5 % at stage I to 0 % at stage IV. Moreover, the rela-
tive cost of the advanced care phase increased for diag-
noses in more advanced stages, from 14.5 % at stage I to
94.9 % at stage IV.
Discussion
Long-term costs of CRC care were estimated in a cohort
of 699 patients diagnosed and treated for CRC in Spain
in 2000–2006, with follow-up until 30 June 2011. Total
mean long-term cost ranged from €20,708 among in situ
cases, to €47,681 among patients diagnosed at stage III.
The estimated costs increased in more advanced stages
up to stage III and then decreased substantially in stage
IV. Advanced disease stages were associated with a de-
crease in the relative weight of the cost of the initial and
continuing care phases, but an increase in advanced dis-
ease cost. As expected, the difference between the mean
observed costs and estimated mean long-term costs de-
creased in advanced stages, reflecting the shorter sur-
vival time of patients diagnosed with advanced tumours.
In the last fifteen years, various studies have estimated
the long-term cost of CRC treatment in the international
context, with different objectives, methodologies and
health contexts [18, 22–31]. Some studies have looked at
the estimated cost per patient showing a positive trend
as disease stage progressed [23, 24, 26, 28, 31]. This as-
sociation remained positive up to stage III, with a de-
crease in stage IV, mainly due to the lower weight of
surgery costs at this stage. In addition, the high costs for
patients diagnosed at earlier stages reflect increased
medical costs during the initial care phase, together with
longer survival times compared to patients diagnosed at
more advanced stages. However, in the studies carried
out by Etzioni et al. [22] and Lang et al. [30], mean life-
time cancer-related costs decreased as disease stage pro-
gressed. In these studies, costs associated with CRC
Table 2 Survival time by TNM stage at diagnosis
TNM
Stage
N Deaths Censored cases Survival time (months) Follow-up time (months)
N (%) N (%) Mean [SD] Mean [SD]
In situ 40 - 40 (100.0) 137.5 [−] 56.6 [34.3]
I 87 8 (9.2) 79 (90.8) 126.1 [35.9] 73.9 [35.0]
II 179 53 (29.6) 126 (70.4) 98.7 [59.4] 56.4 [40.3]
III 174 80 (46.0) 94 (54.0) 80.1 [61.2] 50.3 [37.0]
IV 144 118 (81.9) 26 (18.1) 21.2 [39.2] 14.4 [21.3]
Unknown 75 33 (44.0) 42 (56.0) 68.7 [73.7] 28.3 [38.4]
Total 699 292 (41.8) 407 (58.2) 82.3 [66.6] 45.4 [39.9]
SD standard deviation
Table 3 Observed mean cost, KMSA estimation, cost extrapolation and mean long-term cost by TNM stage at diagnosis (€, 2005)
TNM
Stage
N Censored cases Observed
mean
cost
KMSA
estimation
cost
Cost
extrapolation
Total long-term costs
N (%) Mean 95 % CI
In situ 40 40 (100.0) 9634 17,692 3016 20,708 (16,902; 25,500)
I 87 79 (90.8) 23,999 27,272 4485 31,757 (27,172; 36,731)
II 179 126 (70.4) 31,262 37,247 3869 41,116 (38,313; 43,979)
III 174 94 (54.0) 41,550 44,934 2747 47,681 (43,439; 52,551)
IV 144 26 (18.1) 27,873 28,050 10 28,061 (26,533; 29,694)
Unknown 75 42 (56.0) 10,363 11,976 521 12,497 (10,411; 14,842)
Global 699 407 (58.2) 28,741 32,772 2435 35,207 (33,521; 36,989)
KMSA Kaplan-Maier sample average, CI confidence interval
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were estimated as the difference in the total costs of all
medical care between matched cancer patients and con-
trol patients. They found that the excess lifetime costs
for stage IV cases were very low, reflecting the fact that
increased costs from the time of diagnosis were offset by
their low survival and the costs for controls over their
additional years of life. In any case, the results of these
two studies are somewhat lower than ours or those from
Brown et al. [23] because unrelated future medical costs
are accounted for in the total lifetime projected cost.
In line with what was found in different studies [23–25],
higher costs were found during the initial care phase
(basically due to surgical procedures) and the advanced
care phase due to hospitalisations, chemotherapy, and pal-
liative care, with the exception of patients diagnosed in
situ and at stage I, where the continuing care phase repre-
sented almost 50 % of total mean lifetime cost. Maroun et
al. [24] found that initial treatment accounted for 49 % of
the total cost, while 28 and 27 % of the total cost pertained
to the terminal phase for colon and rectum cancers, re-
spectively. Our results show that, in stages in situ, I and II,
the mean cost of the initial phase was higher than in the
advanced phase, while the cost of the initial phase was
lower in stages III and IV. In the study of Lang et al. [30],
the mean cost of the initial phase was greater than the ad-
vanced phase regardless of stage at diagnosis.
Most long-term cost studies of CRC have been con-
ducted in the United States [6–9], but to our knowledge,
there are no such studies in Spain. Despite the recog-
nised need for specific studies in Spain, there is a lack of
appropriate sources of information to perform these
studies. There are not many hospitals with key informa-
tion sources to assess hospital costs of cancer care: a
hospital cancer registry, clinical-administrative informa-
tion system and analytical accounting system. Cots et al.
[12] examined the costs of CRC treatment for a cohort
of patients diagnosed with CRC in Hospital del Mar in
2000 by stage at diagnosis and phase of care. A cost
methodology based on clinical information was used,
but it was a retrospective study that did not take into ac-
count patient withdrawals during the follow-up period,
and it did not have complete survival information on the
cases included in the analysis. Despite this limitation,
this analysis provided a basis for a long-term cost
Fig. 1 Observed mean cost and and mean long-term cost by TNM stage at diagnosis (€, 2005)
Table 4 Long-term cost of CRC treatment by TNM stage at diagnosis and phase of care (€, 2005)
TNM
Stage
N Initial phase Continuing phase Advanced-care phase Total long-term cost
Mean (%) Mean % Mean % Mean %
In situ 40 3852 (18.6) 11,593 (56.0) 5263 (25.4) 20,708 (100.0)
I 87 11,104 (35.0) 16,038 (50.5) 4615 (14.5) 31,757 (100.0)
II 179 13,251 (32.2) 11,100 (27.0) 16,764 (40.8) 41,116 (100.0)
III 174 14,182 (29.7) 6524 (13.7) 26,975 (56.6) 47,681 (100.0)
IV 144 1429 (5.1) - 26,632 (94.9) 28,061 (100.0)
Unknown 75 1119 (9.0) 514 (4.1) 10,863 (86.9) 12,497 (100.0)
Global 699 8740 (24.8) 5945 (16.9) 20,522 (58.3) 35,207 (100.0)
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estimation. Because recently introduced drugs have sig-
nificantly increased treatment costs, some studies have
focused on chemotherapy treatments or on a particular
phase of the disease [10, 11].
The methodology used in this study combines a non-
parametric evaluation of observed data over the initial
years post-diagnosis with model-based estimates for
those who survive beyond the period of data observa-
tion. This methodology differs from that used in the
American studies, where the costs associated with CRC
were estimated from the difference in the total costs of
all medical care between matched cancer patients and
control patients [18, 22, 23, 25, 27, 28, 30–32]. Therefore,
the estimated attributable costs reflect the excess costs for
CRC patients relative to a set of matched controls, rather
than strictly the disease-related or attributable costs.
Another difference with these studies is the definition
of the phases of care. In previous studies, the duration
of care phases was fixed and equal for all patients (6/
12 months for the initial care phase, and the last
12 months for the advanced care phase). The definition
of phases was based on the observed U-shaped patterns
of costs following diagnosis in a previous study (highest
costs in the initial and terminal phases of care and lower
costs in the continuing phase of care) [33]. These phases
were chosen to coincide with clinically relevant events.
In our study, the duration of the three phases for each
patient was determined through an algorithm based on
clinical information, which can reflect and predict disease
progression more accurately. This approach could affect
the phase of care cost estimation obtained (e.g. the cost of
the advanced phase of care, with a longer duration, was
greater in all stages compared to the estimation obtained
through the last 12 months of life; data not shown).
This study is also strengthened by the sources of infor-
mation used to measure costs. By contrast, most other
studies assessed heath care costs by reviewing expenses or
charges made to patients, rather than actual costs [32].
Still, our results should be interpreted in light of the
model assumptions and their potential limitations. Some
of these limitations are common to all studies that rely
on clinical-administrative databases, such as potential
coding errors and incomplete data. Moreover, current
higher complexity chemotherapy treatments were not
included. The study design required a long follow-up
period, complicating the consideration of recent treat-
ments in the analysis. In any case, this fact would in-
crease the cost of the treatment of CRC.
Another limitation is that our results respond to the
organisational characteristics and clinical practice of one
centre, which limits the generalisability of the study find-
ings. However, the Hospital del Mar is a public acute
care reference hospital in the treatment of cancer, which
follows the clinical guidelines of the Spanish National
Health System. Moreover, only a few hospitals in Spain
have the essential information sources to carry out this
type of studies: a hospital cancer registry, clinical-
administrative information system and analytical account-
ing system. Further studies should be conducted adapting
our methods to other patient populations and settings.
Conclusions
This study provides long-term cost estimates for CRC
treatment by stage at diagnosis and phase of care. Esti-
mated costs increased as disease stage progressed up to
Stage III. The highest costs were found during the initial
and advanced care phases, with the exception of in situ
and stage I patients, where the mean cost of continuing
phase represented almost 50 % of total mean long-term
cost. As far as we know, ours is the first study that pro-
vides long-term costs for CRC treatment based on clin-
ical practice in Spain. This cost analysis is a baseline
study that will provide a useful source of information for
future studies on cost-effectiveness and on the budget
impact of different therapeutic innovations in Spain.
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